Furthermore, cytoplasmic expression of CD133 was associated with a higher rate of peritoneal, lymphatic, and hematogenous metastasis, poor prognosis, and chemoresistance compared with the gastric tumors that express CD133 luminally or that are CD133 negative. This evidence concerns the gene PROM1 and gastric neoplasm.